The drug RHB-102, a type of ondansetron, is designed as an extended-release tablet for treating nausea and vomiting. It comes in 12mg and 24mg doses and is intended for patients undergoing chemotherapy, radiotherapy, or those with certain digestive issues like acute gastroenteritis and IBS-D.
RedHill Biopharma has partnered with Hyloris Pharmaceuticals to develop and market RHB-102 globally, excluding North America. RedHill will receive payments and royalties from Hyloris, which will handle the drug’s development and sales in its designated areas.
RedHill is also working on getting approval from the US FDA. The UK’s health agency has already given positive feedback, paving the way for RHB-102 to become the first 24-hour ondansetron tablet for treating nausea from chemotherapy and radiotherapy.
The drug has been successful in US trials for treating gastroenteritis and IBS-D. Additionally, RedHill received $1.7 million from the US government to develop another drug, opaganib, for treating radiation syndrome.